Abstract
IDegAsp is a fixed combination of degludek and aspart insulins. It is a mixture of long-acting basal (degludek) and bolus (aspart) insulin.
Compared to premixed insulins (single insulin suspension), its short component has a rapid onset of action (postprandial need) and the basal component has a flat and stable profile of action (basal need). The effectiveness of IDegAsp treatment is at least comparable to other insulin regimens, but it is safer (lower risk of hypoglycaemia, lower need for a total insulin dose) while achieving lower fasting blood glucose (degludec effect).
Other advantages of IDegAsp over premixed insulins are ease of administration and flexibility of administration with food. IDegAsp is especially suitable for type 2 diabetics for whom we need to achieve the best possible glycemic control with the lowest possible risk of hypoglycemia.